{"id":20233,"date":"2023-07-11T03:49:00","date_gmt":"2023-07-11T03:49:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4153982_CN53982_0"},"modified":"2023-07-11T03:49:00","modified_gmt":"2023-07-11T03:49:00","slug":"doer-biologics-announces-license-agreement-with-biontech","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=20233","title":{"rendered":"Doer Biologics Announces License Agreement with BioNTech"},"content":{"rendered":"<div id=\"dvContent\" readability=\"84.669156883671\">\n<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1969220\/Logo.jpg?p=medium600\" border=\"0\" alt title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">HANGZHOU, China<\/span>, July 11, 2023 \/PRNewswire\/ &#8212; Zhejiang Doer Biologics Co., Ltd. (&#8220;Doer Bio&#8221;), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announced that it has entered into a license agreement with BioNTech SE&nbsp;(Nasdaq: BNTX, &#8220;BioNTech&#8221;).<\/span><\/p>\n<p>Under the terms of the agreement, Doer Bio will grant BioNTech a worldwide license to utilize one of Doer Bio&#8217;s innovative discoveries to research, develop, manufacture, and commercialize innovative biotherapeutics against an undisclosed target. Doer Bio will receive an upfront payment and will be eligible for potential development, regulatory, and commercial milestone payments.<\/p>\n<p>&#8220;This license agreement with BioNTech is a great demonstration of the enormous potential of Doer Bio&#8217;s platform technologies, which has been well validated by extensive preclinical research and ongoing clinical studies,&#8221; said <span class=\"xn-person\">Yanshan Huang<\/span>, Ph.D., founder and Chief Executive Officer of Doer Bio.<\/p>\n<p>&#8220;We are thrilled to work with BioNTech, a globally leading biopharmaceutical company, to translate our technologies and discoveries into novel therapies. We are looking forward to working with BioNTech to advance this innovation into clinic and ultimately benefit patients worldwide,&#8221; commented <span class=\"xn-person\">Yongliang Fang<\/span>, Ph.D., Chief Operating Officer of Doer Bio.<\/p>\n<p><b>About Doer Bio<\/b><\/p>\n<p>Zhejiang Doer Biologics Co., Ltd. (&#8220;Doer Bio&#8221;) is a clinical stage biopharmaceutical company that focuses on the discovery and development of multi-domain based multi-specific biotherapeutics to address unmet medical need in the field of metabolic diseases and cancers.<\/p>\n<p>Doer Bio has developed multiple proprietary platform technologies, including xLONGylation\u00ae, MultipleBody\u00ae, AccuBody\u00ae, and SMART-VHHBody.<\/p>\n<p>For more information about Doer Bio, please visit <a href=\"https:\/\/www.doerbio.com\/\" target=\"_blank\" rel=\"nofollow noopener\">www.doerbio.com <\/a><span id=\"spanHghlt8a32\">or contact <a href=\"mailto:bd@doerbio.com\" target=\"_blank\" rel=\"nofollow noopener\"><span>bd@doerbio.com<\/span><\/a>&nbsp;.&nbsp;<\/span><\/p>\n<\/p><\/div>\n<p>Source: Zhejiang Doer Biologics Co., Ltd.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>HANGZHOU, China, July 11, 2023 \/PRNewswire\/ &#8212; Zhejiang Doer Biologics Co., Ltd. (&#8220;Doer Bio&#8221;), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announced that it has entered into a license agreement with BioNTech SE&nbsp;(Nasdaq: BNTX, &#8220;BioNTech&#8221;). Under the terms of the agreement, Doer Bio will grant BioNTech a worldwide [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-20233","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Doer Biologics Announces License Agreement with BioNTech - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=20233\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Doer Biologics Announces License Agreement with BioNTech - My Blog\" \/>\n<meta property=\"og:description\" content=\"HANGZHOU, China, July 11, 2023 \/PRNewswire\/ &#8212; Zhejiang Doer Biologics Co., Ltd. (&#8220;Doer Bio&#8221;), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announced that it has entered into a license agreement with BioNTech SE&nbsp;(Nasdaq: BNTX, &#8220;BioNTech&#8221;). Under the terms of the agreement, Doer Bio will grant BioNTech a worldwide [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=20233\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-11T03:49:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/1969220\/Logo.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=20233#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=20233\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Doer Biologics Announces License Agreement with BioNTech\",\"datePublished\":\"2023-07-11T03:49:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=20233\"},\"wordCount\":276,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=20233#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1969220\\\/Logo.jpg?p=medium600\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=20233\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=20233\",\"name\":\"Doer Biologics Announces License Agreement with BioNTech - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=20233#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=20233#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1969220\\\/Logo.jpg?p=medium600\",\"datePublished\":\"2023-07-11T03:49:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=20233#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=20233\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=20233#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1969220\\\/Logo.jpg?p=medium600\",\"contentUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1969220\\\/Logo.jpg?p=medium600\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=20233#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Doer Biologics Announces License Agreement with BioNTech\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Doer Biologics Announces License Agreement with BioNTech - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=20233","og_locale":"en_US","og_type":"article","og_title":"Doer Biologics Announces License Agreement with BioNTech - My Blog","og_description":"HANGZHOU, China, July 11, 2023 \/PRNewswire\/ &#8212; Zhejiang Doer Biologics Co., Ltd. (&#8220;Doer Bio&#8221;), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announced that it has entered into a license agreement with BioNTech SE&nbsp;(Nasdaq: BNTX, &#8220;BioNTech&#8221;). Under the terms of the agreement, Doer Bio will grant BioNTech a worldwide [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=20233","og_site_name":"My Blog","article_published_time":"2023-07-11T03:49:00+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/1969220\/Logo.jpg?p=medium600","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=20233#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=20233"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Doer Biologics Announces License Agreement with BioNTech","datePublished":"2023-07-11T03:49:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=20233"},"wordCount":276,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=20233#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/1969220\/Logo.jpg?p=medium600","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=20233","url":"https:\/\/transmediavictoria.net.au\/?p=20233","name":"Doer Biologics Announces License Agreement with BioNTech - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=20233#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=20233#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/1969220\/Logo.jpg?p=medium600","datePublished":"2023-07-11T03:49:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=20233#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=20233"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=20233#primaryimage","url":"https:\/\/mma.prnasia.com\/media2\/1969220\/Logo.jpg?p=medium600","contentUrl":"https:\/\/mma.prnasia.com\/media2\/1969220\/Logo.jpg?p=medium600"},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=20233#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Doer Biologics Announces License Agreement with BioNTech"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/20233","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20233"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/20233\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20233"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20233"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}